|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Mylan Laboratories Inc. (NYSE: MYL), a leading generic pharmaceutical company. |
|---|---|
| Transferring Party | The generic drug business of Merck KGaA, a large international drug company. |
| Sector | Biopharmaceuticals |
| Date | October 2, 2007 |
| Analysis Creates a vertically and horizontally integrated generics and specialty pharmaceuticals leader with a diversified revenue base and a global footprint. Pro forma combined '06 revenues of - $4.2b, EBITDA of - $1.0b and about 10,000 employees, immediately making it among the top tier of global generic companies. Deal value -- $6.7b. In '06. Merck Generics' sales were $2.5b (2.7x) and EBITDA $450m (14.9x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |